用/不用放射治疗的化疗对食道状细胞癌IVb阶段的有效性:基于人口的向试验仿真研究
Yao-Hung Kuo1, Chen-Yuan Lin2,3, Yao-Ching Wang4
1Department of Radiation Oncology, E-Da Hospital, Kaohsiung, Taiwan, ROC.
Discover oncology
|May 6, 2025
概括
与单独的化疗相比,化疗放射治疗显著改善了第四阶段b食道状细胞癌 (ESCC) 患者的整体存活率. 这种组合疗法为晚期ESCC提供了有前途的治疗方法.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 第IVb期食道状细胞癌 (ESCC) 的最佳治疗策略仍然不确定.
- 结合放射治疗和全身治疗的有效性需要进一步研究.
研究的目的:
- 为了评估一次性化疗和单独化疗对IVb期ESCC患者的疗效.
- 为了比较两个治疗组之间的整体存活率和食道癌死亡率.
主要方法:
- 使用台湾癌症注册表 (2011-2021) 的回顾性队列研究.
- 用于患者选择和分析的目标试验仿真框架.
- 整体存活率 (OS) 作为主要终点;食道癌死亡率作为次要终点.
主要成果:
- 总共分析了5294名患者;5065人接受化学放射治疗,229人仅接受化疗.
- 化疗放射治疗与明显改善的生存状况相关 (HR 0.46;95% CI 0.41-0.52;p < 0.0001).
- 二级终点和补充分析也有利于化疗放射治疗组.
结论:
- 初级化疗辐射疗法在IVb期ESCC患者的整体存活率高于单独化疗.
- 这一发现支持在这种患者群体中使用化学放射治疗.
- 预计正在进行的临床试验的结果将进一步验证这些结果.
相关概念视频
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Tumor Immunotherapy
401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
151
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
151
Barrett Esophagus-II: Clinical Manifestations and Management
77
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
77
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


